Anti-diabetic rosiglitazone remodels the adipocyte transcriptome by redistributing transcription to PPARγ-driven enhancers

Rosiglitazone (rosi) is a powerful insulin sensitizer, but serious toxicities have curtailed its widespread clinical use. Rosi functions as a high-affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ), the adipocyte-predominant nuclear receptor (NR). The classic model, involving b...

Descripción completa

Detalles Bibliográficos
Autores principales: Step, Sonia E., Lim, Hee-Woong, Marinis, Jill M., Prokesch, Andreas, Steger, David J., You, Seo-Hee, Won, Kyoung-Jae, Lazar, Mitchell A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018489/
https://www.ncbi.nlm.nih.gov/pubmed/24788520
http://dx.doi.org/10.1101/gad.237628.114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018489/
https://www.ncbi.nlm.nih.gov/pubmed/24788520
http://dx.doi.org/10.1101/gad.237628.114

Ejemplares similares